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INTRODUCTION
Renal cell carcinoma is characterized by a lack of early
warning signs, resulting in a high proportion of metastasis
at diagnosis. Relapse occurs in 30% to 50% of patients with
completely resected renal cell carcinoma after a radical neph-
rectomy. Metastatic renal cell carcinoma (mRCC) is a disease
with a poor prognosis and a 5-yr survival rate of less than
10% and is resistant to chemotherapy or radiotherapy (1).
Many immunotherapy protocols have been investigated
since Rosenberg and colleagues discovered the clinical efficacy
of high-dose bolus interleukin-2 (IL-2) in the treatment of
patients with mRCC (2). With an overall response rate of
approximately 20% and a durable complete response, the
use of high-dose bolus IL-2 has been the best treatment for
mRCC. Thus, it remained as the only U.S. Food and Drug
Administration-approved drug for the treatment of meta-
static renal cancer for more than a decade before the intro-
duction of new drugs (3). However, some investigators have
encountered significant multi-system toxicities resulting in
treatment-related mortality, and consequently, its applica-
tion has been limited to the highly selected patients treated
at specialized centers (4). 
The pronounced toxicities of high-dose bolus IL-2 treat-
ment prompted the development of regimens with subcu-
taneous injections of IL-2. In addition, attempts were also
made to improve treatment efficacy by adding interferon-
(IFN- ) and combinations of low-dose IL-2 and other che-
motherapeutic agents (5-8). 
Given the toxicity and expense, treatment should be lim-
ited to patients most likely to benefit from immunotherapy.
Therefore, many groups have attempted to determine the
immunologic prognostic factors as well as to establish clini-
cal prognostic factors for patients with mRCC who receive im-
munotherapy (9-12). 
It is believed that antitumor effects of IL-2 are due to sev-
eral mechanisms: it stimulates the generation of natural killer
(NK) cells; it enhances not only the cytotoxic activities of T
cells but also the T-helper cells and eosinophils (13-15). IL-2
based immunotherapy results in varying degrees of lympho-
cytosis and eosinophilia in each patient. 
The aims of the present study were to evaluate the clinical
effectiveness of an IL-2, IFN- , and 5-fluorouracil (5-FU)
combination immunotherapy regimen and to correlate the
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Analysis of Changes in the Total Lymphocyte and Eosinophil Count
during Immunotherapy for Metastatic Renal Cell Carcinoma: 
Correlation with Response and Survival
The aims of this study were to analyze lymphocyte and eosinophil counts in con-
secutive peripheral blood samples taken during immunotherapy for metastatic renal
cell carcinoma (mRCC) and to correlate the findings with objective response and
survival. A total of 40 patients with mRCC who received immunotherapy with inter-
leukin-2, interferon- , and 5-fluorouracil were analyzed. Objective responses were
observed in 14 patients, including 2 (5%) who showed a complete response (CR)
and 12 (30%) who showed a partial response (PR). Eleven patients (27%) achieved
stable disease (SD), and 15 patients (38%) had progressive disease (PD). Changes
from baseline in the total lymphocyte counts were significantly higher in the respond-
ing patients (CR+PR+SD) than in the non-responding patients (PD) (p=0.017), but
no difference was seen in the total eosinophil counts (p=0.275). Univariate analy-
sis identified the Eastern Cooperative Oncology Group (ECOG) performance sta-
tus (p=0.017), the presence of a primary renal tumor (p<0.001) and the peripheral
lymphocyte counts at week 4 (p=0.034) as prognostic factors, but a low ECOG
performance status (p=0.003) and the presence of a primary renal tumor (p=0.001)
were identified as independent poor prognostic factors by multivariate analysis. This
study provides further evidence that changes in blood lymphocyte counts may serve
as an objective indicator of objective responses.
Key Words : Renal Cell Carcinoma; Interleukin-2; Interferon-alpha; Lymphocytes; Eosinophils
Received : 13 February 2007
Accepted : 1 May 2007Immunotherapy for Renal Cancer S123
objective response and survival with the changes in the blood
lymphocyte and eosinophil counts during treatment. 
MATERIALS AND METHODS
Patient selection 
From August 2001 to July 2006, 40 patients with histolo-
gically confirmed and measurable progressive mRCC were
recruited for this study. Patient assessment at entry into the
study consisted of a clinical evaluation, a complete blood cell
count, blood chemistry studies, urinary status, radionuclide
bone scan, abdominal, thoracic and cranial computerized
tomography (CT), and electrocardiography. Of these patients,
nephrectomy was performed in 37 patients before treatment
with immunotherapy. Three patients did not wish to under-
go surgery and embolization was performed following the
biopsy. 
The eligibility criteria included an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1, a
life expectancy of at least 3 months, adequate blood counts
(hemoglobin greater than 10 g/dL, a white blood cell count
greater than 4,000/mL and a platelet count greater than
100,000/mL), adequate renal and hepatic functions (serum
creatinine 1.4 mg/dL or less, serum total bilirubin 1.2 mg/
dL or less, and serum alanine aminotransferase 40 IU/L or
less), and adequate cardiac and pulmonary function. Exclu-
sion criteria included cardiovascular disease, hematopoietic,
pulmonary, hepatic or renal dysfunction, ECOG performance
status >1, active infection, autoimmune disease, HIV and
hepatitis, concomitant therapy with drugs influencing im-
munity, and prior malignancies or brain metastases. All pa-
tients provided written, informed consent before study entry.
Treatment plan 
Immunotherapy was given with the initial 4 weeks con-
sisting of treatment with subcutaneous IL-2 (weeks 1 and 4:
20×106 U/m2 on day 1, 3 and 5; weeks 2 and 3: 5×106
U/m2 on days 1, 3 and 5) and treatment with subcutaneous
IFN- (weeks 1 and 4: 6×106 U/m2 on day 1; weeks 2 and
3: 6×106 U/m2 on days 1, 3 and 5) injections, followed by
4 weeks of injections of subcutaneous IFN- (weeks 5 to 8:
9×106 U/m2 on days 1, 3 and 5) and intravenous bolus in-
jections of 5-FU (weeks 5 to 8: 750 mg/m2 on day 1) (16).
The doses in weeks 1 and 4 were administered on an inpa-
tient basis, with the rest of the treatment administered on
an outpatient basis, except in cases of excessive toxicity.
Collection of blood samples 
Blood samples were obtained at baseline and on day 6 of
every week throughout the treatment. Total and differential
white blood cell counts were determined for all patients. 
Response assessment 
Patients were assessed by radiological evaluation or by phy-
sical measurement of all sites of disease following the com-
pletion of the immunotherapy regimen. The clinical response
was evaluated according to the World Health Organization
(WHO) criteria (17). After immunotherapy, metastasecto-
my was considered for patients with residual disease and who
presented with solitary or a few respectable metastases with
an acceptable performance status. Response duration was
measured from the first observation, and time to survival
was counted from the beginning of treatment. 
Treatment toxicity 
Systemic toxicity of the treatment regimen was determined
every week using a grading system according to the WHO
classification, namely blood cell count and serum biochemi-
cal tests of hepatic and renal function (17). Thyroid stimulat-
ing hormone (TSH), triiodothyronine (T3), thyroxine (T4),
and human anti-thyroid antibodies were assayed in all pati-
ents before and after immunotherapy to quantify possible
adverse effects on thyroid function. 
Statistical analysis 
The primary end-points of the study were therapeutic res-
ponse and overall survival after immunotherapy. The abso-
lute number of blood lymphocyte and eosinophil counts were
analyzed as the dependent variables in a general linear model
repeated measures methods to evaluate the associations of
these variables and the clinical response following immu-
notherapy. To evaluate the predictive value of measured blood
lymphocyte counts at each time (baseline and weeks 1 to 4)
for therapeutic response, receiver operating characteristic
(ROC) curves were generated and areas under the curves
(AUC) were calculated for the measured lymphocyte counts
at each time. Kaplan-Meier survival curves for overall sur-
vival were generated, and the log-rank test was used to com-
pare survival according to the variable. The Cox proportion-
al hazards regression model was used to estimate the relative
importance of the variables. For all statistical analyses p<
0.05 was considered significant. 
RESULTS
Patient characteristics and response to treatment 
Demographic and clinical characteristics are summarized in
Table 1. The median age of the 40 patients was 56 yr (range,
36-72). All patients included in this study showed a clearS124 I.G. Jeong, K.S. Han, J.Y. Joung, et al.
cell histology, and sarcomatoid differentiation was seen in 2
patients. The overall response rate was 35% (2 complete res-
ponses and 12 partial responses), stable disease was achieved
in 11 (27%) patients, and progressive disease occurred in 15
(38%). Complete responses were found only in patients with
a single lung metastasis, and the duration of complete remis-
sion was 33 and 36 months, respectively. 
Changes in the blood total lymphocyte and eosinophil
count 
Total lymphocyte counts were significantly higher in res-
ponding patients (CR+PR+SD) than in non-responding
patients (PD) (Fig. 1). No difference was seen in the total
eosinophil counts (Fig. 2). Among the serial blood lympho-
cyte counts at baseline and for each week, the total lympho-
cyte count at week 4 was the most predictive of therapeutic
response. The ROC curve for the lymphocyte count at week
4 demonstrated the most significant predictive ability (AUC
0.84, 95% confidence interval [CI] 0.76 to 0.91). The AUC
for the baseline, and weeks 1, 2, and 3 were 0.68 (95% CI
0.60 to 0.77), 0.49 (95% CI 0.40 to 0.59), 0.74 (95% CI
0.66 to 0.82), and 0.68 (95% CI 0.60 to 0.77), respectively. 
Survival 
The median follow-up period after the start of the immu-
notherapy was 16 months. The overall survival rate was 61%
(95% CI 53% to 70%), 39% (95% CI 31% to 49%), and
27% (95% CI 18% to 36%) at 1, 2, and 3 yr, respectively,
and median survival was 15 months (Fig. 3). On univariate
analysis unfavorable prognostic variables for overall survival
were low ECOG performance status, the presence of a pri-
mary renal tumor, and a low peripheral lymphocyte count
at week 4. In patients with a lymphocyte count higher than
1,900 n/ L, the 3-yr survival rate was 36%, compared to
15% when the lymphocyte count was 1,900 n/ L or less
(Table 2 and Fig. 4). On multivariate analysis low ECOG
performance status and the presence of a primary renal tumor
were associated with decreased overall survival (Table 3). 
ECOG, Eastern Cooperative Oncology Group.
Characteristics No. %
Age 
≤60 27 68 
>60 13 32 
Sex 
Male 34 85 
Female 6 15 
ECOG Performance status 
0 28 70 
1 12 30 
Symptom  
Symptomatic 24 60 
Asymptomatic 16 40 
Metastasis-free interval 
≤1 yr   30 75 
>1 yr 10 25 
Lung metastasis only 
Yes 24 60 
No 16 40 
Bone metastasis 
Yes 11 28 
No 29 72 
Liver metastasis 
Yes 5 13 
No 35 87 
Presence of primary renal tumor 
Yes 3 8 
No 37 92 
Prior metastatectomy 
Yes 9 23 
No 31 77
Table 1. Baseline characteristics of patients (n=40)
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Fig. 1. Changes in the blood total lymphocyte counts in the first
month during immunotherapy. 
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Fig. 2. Changes in the blood total eosinophil counts in the first
month during immunotherapy.Immunotherapy for Renal Cancer S125
Toxicity 
The most common side effects were flu-like symptoms,
fatigue, mucositis, diarrhea, vesicle, changes in leukocyte,
hemoglobin, and platelet levels, and nausea during the treat-
ment. Table 4 shows a detailed description of systemic toxi-
cities and their severity. In all patients treatment-related sys-
temic toxicity resolved after the end of the therapeutic regi-
men. No patient had grade 4 toxicity, and there were no treat-
ment-related deaths. 
DISCUSSION
Because of the significant toxicity and its high cost, it is
very important to select patients with mRCC who may ben-
efit mostly from immunotherapy prior to treatment. With
regard to the histologic subtype, responses to immunother-
apy are most frequently seen in patients with renal cell car-
cinoma of clear cell histology. Among the clear cell subtypes,
the response to IL-2 was associated with the presence of al-
veolar features and the absence of granular or papillary fea-
tures (11). Gez and colleagues identified good performance
status, absence of bone metastases, and no other concomitant
Risk factor
Patients 
(No.)
Median 
survival
(months)
p
Factors prior to immunotherapy 
ECOG performance status 0.017
02 8 2 8
1 12 9
Symptom 0.4
Symptomatic 24 15
Asymptomatic 16 15
Metastasis-free interval 0.124
≤1 yr  30 10
>1 yr  10 30
Lung metastasis only   0.804 
Yes  24      21
No 16 15
Bone metastasis 0.982 
Yes 11 9
No 29 18
Liver metastasis 0.501 
Yes 5 8
No 35 15
Number of visceral metastasis 0.516
≥21 1 1 5
<2 29 18
Presence of primary renal tumor <0.001 
Yes 3 3
No  37       18
Prior metastatectomy        0.376 
Yes  9        15
No 31 15
Hemoglobin 0.092
<Normal 24 9
Normal 16 26
Platelet 0.983
Normal 35 18
>Normal 5 13
Alkaline phosphatase 0.204
Normal 30 18
>Normal 10 6
Factor during immunotherapy 
Total lymphocyte count at week 4   0.034 
>1,900 n/ L 21           24
≤1,900 n/ L 19 17
Factor after immunotherapy 
Metastatectomy               0.521 
Yes 12 26
No 28 13
Table 2. Univariate survival analysis of clinical variables before
and after immunotherapy
ECOG, Eastern Cooperative Oncology Group.
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Fig. 3. Overall survival of the 40 patients with metastatic renal cell
carcinoma treated with immunotherapy. 
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Fig. 4. Survival curves by blood total lymphocyte counts at week 4.
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comorbidity as important predictors of response in patients
receiving immunochemotherapy. A prior nephrectomy had
no influence on response to treatment in their study (18).
Recent data from the Cytokine Working Group phase III
trial have suggested that patients with bone or liver metas-
tasis or a primary tumor in place might little benefit mini-
mally from a lower-dose IL-2 regimen. Based on their study,
it was believed that high-dose IL-2 therapy was superior to
a low-dose IL-2 regimen in selected patients with an access
to such treatment (19). In our study, ECOG performance
status and a prior nephrectomy were independent predictors
of survival in patients receiving immunotherapy.
The results from the present study demonstrated a higher
response rate of 35% and three-year survival rate of 27% for
this regimen, which are similar to those described by other
investigators (18, 20). There may be a possible explanation
for the satisfactory results of this study. First of all, the majori-
ty of patients had an excellent ECOG performance status (0
to 1). In addition, all of the patients had a clear cell histolo-
gy, which was regarded as a good predictor of response to
IL-2 therapy, and a large number of patients had undergone
a prior nephrectomy. Even though a higher response rate
was observed in the present study, the long-term survival of
patients was poor. Possible explanation for poor survival is
that in this study the response to treatment was assessed fol-
lowing the completion of the first cycle. Subsequently, many
of responding patients to the first cycle of immunotherapy
progressed eventually.
Considering the anti-tumor activity of host immune cells,
it has been speculated that the host immune system plays
an important role in immunotherapy for the treatment of
patients with mRCC. Most recently, Donskov and colleagues
identified clinical and immunologic independent predictors
of survival for patients with mRCC receiving IL-2. In this
study, lactate dehydrogenase, lymph node metastases, hemo-
globin, Karnofsky performance status, and bone metastases
were identified as clinical independent prognostic factors.
Furthermore, a high blood neutrophil count, the presence of
intratumoral neutrophils, and a low intratumoral CD57
+NK
cell count were also identified as independent poor prognos-
tic immunologic factors (12). 
After the administration of IL-2, the number of lympho-
cytes in the peripheral blood increases following transient
lymphocytopenia for about 36 to 48 hr. The degree of lym-
phocytosis is variable (21). It is known that a greater lym-
phocyte increase has been observed after IL-2 therapy in pa-
tients with mRCC who achieve an objective response, as seen
in several studies. Furthermore, elevated baseline inflamma-
tory markers prevent IL-2-induced lymphocytosis and results
in tumor progression (22). With regard to the role of lym-
phocytosis in predicting the response to IL-2, a significant
positive correlation between the absolute number of periph-
eral blood lymphocytes after 2 weeks of treatment and an
objective response was demonstrated (9). Similarly, Fuma-
galli and colleagues also found that the baseline and the ma-
ximum lymphocyte count on therapy were associated with
overall survival (10). 
Our understanding of the mechanism by which IL-2 me-
diates its antineoplastic actions is incomplete. Published
studies have demonstrated an increased number of CD3
+ T
cells and CD57
+ NK cells in responding patients during
immunotherapy. Moreover, these studies have found that
intratumoral CD3
+, CD8
+ T cells and CD57
+ NK cells were
associated with an objective response (9, 23).
In our study, ROC analysis showed that the total lympho-
cyte counts at weeks 2 and 4 were significantly more predic-
tive of a therapeutic response. Because a relatively high-dose
of IL-2 (20×106 U/m2) was administrated at weeks 1 and
4, it is possible that the difference in the predictive value is
related to differences in the administrated dose of IL-2. Tran-
sient lymphocytopenia may be considered as a possible cause
of the low predictive value of the lymphocyte count at week
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.
Risk factor
(categories compared)
Hazard ratio 95% CI p
ECOG performance status  0.033
1 vs. 0  3.4 1.1-10.2
Presence of primary renal tumor 0.001
Yes vs. No 16.3 3.1-85.3
Total lymphocyte count at week 4 0.576
1,900 n/ L vs. >1,900 n/ L 1.3 0.5-3.5
Table 3. Multivariate survival analysis of clinical variables before
and after immunotherapy 
Toxicity
Patients (No.)
Grade 0 Grade 1 Grade 2 Grade 3
Hemotologic 
Hemoglobin 16 10 7 7 
Leukocytes 18 8 9 5 
Platelets 27 5 7 1
Gastrointestinal 
Increased transaminases 31 5 2 2  
Oral mucositis 26 14 0 0 
Nausea/Vomiting 13 12 14 1 
Diarrhea 21 10 8 1 
Renal 
Hypercreatininemia 35 5 0 0 
Cardiac 
Arrhythmia 38 2 0 0 
Pulmonary 30 8 1 1 
Skin 
Cutaneous 15 8 14 3 
Hair 35 5 0 0 
General 
Fever 0 9 23 8 
Chill 18 13 9 0 
Myalgia 3 19 18 0
Table 4. Systemic toxicitiesImmunotherapy for Renal Cancer S127
1. However, the multivariate Cox model using a cutoff for a
total lymphocyte count at week 4 of 1,900 n/ L failed to pre-
dict the survival.
It has been reported that blood eosinophil counts as well
as lymphocyte counts significantly increased after immuno-
therapy with low-dose IL-2 and IFN- for mRCC (15). So
far, an exact role of eosinophil in immunotherapy using IL-
2 remains unclear. Rodgers and colleagues studied the prop-
erties of eosinophils from 16 patients with renal cell carci-
noma who received low-dose IL-2 therapy, and in their study,
the maximum eosinophil count achieved during IL-2 thera-
py is of prognostic significance (24). Moroni and colleagues
also showed that a large eosinophil number predicts the fail-
ure of IL-2 treatment (25). In our study, the absolute num-
ber of eosinophils in peripheral blood increased following
immunotherapy in both responding and non-responding
patients. Although the degree of increase showed a trend
that it was higher in the responding patients, the difference
was not statistically significant.
Several investigators have attempted to confirm the rela-
tionship between changes in blood lymphocyte count and
response to immunotherapy. However, the limitations of
previous studies were the use of heterogeneous immunother-
apy protocols and static analysis on the count at a single point
of time (10, 22). In agreement with previous reports, our
study showed that the blood total lymphocyte count had an
important role in predicting the responses to low-dose IL-2
therapy. On the other hand, in contrast to their studies, all
patients included in our study were homogeneous with regard
to the immunotherapy protocol, and we analyzed the dyna-
mic change of blood lymphocyte and eosinophil counts.
A lymphocyte subset was not determined in our study.
Thus, it is difficult to know which of the lymphocyte sub-
sets correlates with the response to immunotherapy. How-
ever, if we can easily predict the responding patients from
the changes in their blood lymphocyte counts, this will be a
useful way to sub-classify patients treated with immunother-
apy because of its non-invasiveness. In addition, we verified
that the degree of increase in the blood eosinophil counts
did not differ between the responding and non-responding
patients during immunotherapy. Further studies are needed
to confirm whether the changes in the blood lymphocyte
count during immunotherapy are associated with long-term
survival.
In summary, we observed a significant increase in blood
lymphocyte and eosinophil counts during immunotherapy
for mRCC. Total lymphocyte counts were significantly higher
in responding patients than in non-responding patients, but
no difference was observed in the total eosinophil counts.
This study provides further evidence that changes in blood
lymphocyte counts may serve as an objective indicator of
the objective responses when treating patients with mRCC
using immunotherapy.
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